Peter Openshaw

Q: What Schools Are Affiliated With Peter Openshaw

Peter Openshaw is affiliated with the following schools: Imperial College London, University of Oxford, University College London, University of Manchester, King's College London

Peter Openshaw 's AcademicInfluence.com Rankings

Peter Openshaw

Philosophy

#4262

World Rank

#6724

Historical Rank

Logic

#1768

World Rank

#2606

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Peter Openshaw 's Degrees

Masters Medicine University of Manchester
PhD Respiratory Medicine University of Manchester

Why Is Peter Openshaw Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Peter John Morland Openshaw, is a British clinician and scientist specialising in lung immunology, particularly defence against viral infections. He trained in lung diseases and undertook a PhD in immunology before establishing a laboratory at St Mary's Hospital Medical School . He created the academic department of Respiratory Medicine and the Centre for Respiratory Infection at Imperial College and was elected President of the British Society for Immunology in 2014.

(See a Problem?)

Peter Openshaw 's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study (2020) (2363)
Genetic mechanisms of critical illness in COVID-19 (2020) (887)
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 (2020) (884)
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 (2020) (884)
IFITM3 restricts the morbidity and mortality associated with influenza (2012) (680)
Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations (1995) (629)
Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C Mortality Score (2020) (590)
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses (2022) (529)
Reversibility of T helper 1 and 2 populations is lost after long-term stimulation (1996) (484)
Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus (1988) (477)
Mapping the human genetic architecture of COVID-19 (2021) (455)
Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study (2020) (451)
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity (2021) (443)
Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol (2020) (397)
Distinct types of lung disease caused by functional subsets of antiviral T cells (1994) (349)
Tracheostomy in the COVID-19 era: global and multidisciplinary guidance (2020) (310)
Immune Responses and Disease Enhancement during Respiratory Syncytial Virus Infection (2005) (304)
Inhibition of tumor necrosis factor reduces the severity of virus‐specific lung immunopathology (2001) (292)
The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates. (2018) (275)
Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May–September 2009) (2010) (261)
CD8+ T cells control Th2‐driven pathology during pulmonary respiratory syncytial virus infection (1997) (259)
Age at First Viral Infection Determines the Pattern of T Cell–mediated Disease during Reinfection in Adulthood (2002) (259)
Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. (1992) (245)
Flow cytometric measurement of intracellular cytokines. (2000) (234)
RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection (2015) (212)
Faculty Opinions recommendation of Transforming growth factor-beta 'reprograms' the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. (2008) (209)
EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2 (2020) (208)
Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. (1986) (204)
Alveolar Macrophages Are a Major Determinant of Early Responses to Viral Lung Infection but Do Not Influence Subsequent Disease Development (2008) (202)
A potential molecular mechanism for hypersensitivity caused by formalin-inactivated vaccines (2006) (202)
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study (2021) (201)
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study (2021) (201)
Impaired Antibody-mediated Protection and Defective IgA B-Cell Memory in Experimental Infection of Adults with Respiratory Syncytial Virus. (2015) (200)
Intracellular IFN-gamma expression in natural killer cells precedes lung CD8+ T cell recruitment during respiratory syncytial virus infection. (1998) (177)
Respiratory syncytial virus, airway inflammation, and FEV1 decline in patients with chronic obstructive pulmonary disease. (2006) (171)
The microbiology of asthma (2012) (171)
Th1 and Th2 cytokine induction in pulmonary T cells during infection with respiratory syncytial virus. (1996) (166)
Long Covid in adults discharged from UK hospitals after Covid-19: A prospective, multicentre cohort study using the ISARIC WHO Clinical Characterisation Protocol (2021) (165)
Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. (2019) (164)
Global Disease Burden Estimates of Respiratory Syncytial Virus-Associated Acute Respiratory Infection in Older Adults in 2015: A Systematic Review and Meta-Analysis. (2019) (164)
Immunity and immunopathology to respiratory syncytial virus. The mouse model. (1995) (161)
Immunopathogenesis of vaccine-enhanced RSV disease. (2001) (160)
Regulatory T cells expressing granzyme B play a critical role in controlling lung inflammation during acute viral infection (2012) (159)
Latency and persistence of respiratory syncytial virus despite T cell immunity. (2004) (155)
CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells (1992) (154)
Protective and Harmful Immunity to RSV Infection. (2017) (154)
Microbes and mucosal immune responses in asthma (2013) (147)
CD25+ Natural Regulatory T Cells Are Critical in Limiting Innate and Adaptive Immunity and Resolving Disease following Respiratory Syncytial Virus Infection (2010) (146)
Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus (1992) (145)
Eliminating a Region of Respiratory Syncytial Virus Attachment Protein Allows Induction of Protective Immunity without Vaccine-enhanced Lung Eosinophilia (1998) (142)
Inflammatory profiles across the spectrum of disease reveal a distinct role for GM-CSF in severe COVID-19 (2021) (136)
Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study (2021) (136)
Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study (2021) (136)
Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins. (1993) (136)
Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen. (1987) (132)
Influenza Virus Lung Infection Protects from Respiratory Syncytial Virus–Induced Immunopathology (2000) (132)
Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study (2020) (132)
Links between respiratory syncytial virus bronchiolitis and childhood asthma: clinical and research approaches (2003) (130)
Changes in rib cage geometry during childhood. (1984) (129)
Antiviral B cell and T cell immunity in the lungs (2014) (126)
Inhibition of T1/St2 during Respiratory Syncytial Virus Infection Prevents T Helper Cell Type 2 (Th2)- but Not Th1-Driven Immunopathology (2001) (126)
IL-10 Regulates Viral Lung Immunopathology during Acute Respiratory Syncytial Virus Infection in Mice (2012) (122)
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults (2022) (120)
Whole-genome sequencing reveals host factors underlying critical COVID-19 (2022) (120)
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent COVID-19 patients (2020) (120)
Role of CCL5 (RANTES) in Viral Lung Disease (2006) (120)
Outcomes of COVID-19 related hospitalization among people with HIV in the ISARIC WHO Clinical Characterization Protocol (UK): a prospective observational study. (2020) (119)
Evolution of Epitope-Specific Memory CD4+ T Cells After Clearance of Hepatitis C Virus (2002) (118)
The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kd-restricted cytotoxic T lymphocytes from mice primed by infection (1990) (118)
Host genetic determinants of vaccine-induced eosinophilia during respiratory syncytial virus infection. (1998) (116)
Maternal immunisation: collaborating with mother nature. (2017) (113)
Pulmonary defences to acute respiratory infection. (2002) (112)
Differential Chemokine Expression following Respiratory Virus Infection Reflects Th1- or Th2-Biased Immunopathology (2006) (112)
Alpha/Beta Interferon Receptor Signaling Amplifies Early Proinflammatory Cytokine Production in the Lung during Respiratory Syncytial Virus Infection (2014) (112)
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis (2022) (110)
The Role of T Cells in the Enhancement of Respiratory Syncytial Virus Infection Severity during Adult Reinfection of Neonatally Sensitized Mice (2008) (106)
Immunity to RSV in Early-Life (2014) (106)
The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity (2020) (103)
Long‐term persistence and reactivation of T cell memory in the lung of mice infected with respiratory syncytial virus (2001) (101)
Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities (2020) (99)
Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study (2021) (98)
Development and validation of the ISARIC 4C Deterioration model for adults hospitalised with COVID-19: a prospective cohort study (2021) (98)
COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants (2021) (95)
Risk of adverse outcomes in patients with underlying respiratory conditions admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical Characterisation Protocol UK (2021) (94)
Protective and dysregulated T cell immunity in RSV infection☆ (2013) (91)
Mucosal Delivery of a Respiratory Syncytial Virus CTL Peptide with Enterotoxin-Based Adjuvants Elicits Protective, Immunopathogenic, and Immunoregulatory Antiviral CD8+ T Cell Responses1 (2001) (91)
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study (2021) (90)
T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses (2020) (88)
Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins. (1993) (87)
Progression of whole blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in patients with severe influenza (2018) (86)
Regulatory T Cells Prevent Th2 Immune Responses and Pulmonary Eosinophilia during Respiratory Syncytial Virus Infection in Mice (2013) (86)
Ethnicity and Outcomes from COVID-19: The ISARIC CCP-UK Prospective Observational Cohort Study of Hospitalised Patients (2020) (84)
Accumulation of Human-Adapting Mutations during Circulation of A(H1N1)pdm09 Influenza Virus in Humans in the United Kingdom (2014) (81)
Enhanced IL‐4 responses in children with a history of respiratory syncytial virus bronchiolitis in infancy (2002) (80)
Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses (2021) (80)
Open source clinical science for emerging infections (2013) (80)
SARS-CoV-2 co-infection with influenza viruses, respiratory syncytial virus, or adenoviruses (2022) (80)
Predictors of clinical outcome in a national hospitalised cohort across both waves of the influenza A/H1N1 pandemic 2009–2010 in the UK (2012) (79)
COVID‐19: Lessons from SARS and MERS (2020) (79)
Characterisation of in-hospital complications associated with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, multicentre cohort study (2021) (77)
Neutrophilic inflammation in the respiratory mucosa predisposes to RSV infection (2020) (77)
A prenylated dsRNA sensor protects against severe COVID-19 (2021) (76)
Do common childhood infections 'teach' the immune system not to be allergic? (2000) (76)
Mouse γδ TCR+NK1.1+ thymocytes specifically produce interleukin‐4, are major histocompatibility complex class I independent, and are developmentally related to αβ TCR+NK1.1+ thymocytes (1996) (74)
Edinburgh Research Explorer Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study (2020) (72)
Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study (2020) (69)
Group B streptococcus and respiratory syncytial virus immunisation during pregnancy: a landscape analysis. (2017) (69)
Characterization of novel HLA‐DR11‐restricted HCV epitopes reveals both qualitative and quantitative differences in HCV‐specific CD4+ T cell responses in chronically infected and non‐viremic patients (2001) (68)
IL-12 treatment attenuates T helper cell type 2 and B cell responses but does not improve vaccine-enhanced lung illness. (1997) (68)
Immunopathological mechanisms in respiratory syncytial virus disease (2004) (67)
IL-12-Activated NK Cells Reduce Lung Eosinophilia to the Attachment Protein of Respiratory Syncytial Virus But Do Not Enhance the Severity of Illness in CD8 T Cell-Immunodeficient Conditions1 (2000) (66)
The Etiological Role of Common Respiratory Viruses in Acute Respiratory Infections in Older Adults: A Systematic Review and Meta-analysis (2018) (65)
The Etiological Role of Common Respiratory Viruses in Acute Respiratory Infections in Older Adults: A Systematic Review and Meta-analysis (2018) (65)
RSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8+ T cell nonspecific antiviral activity. (2011) (64)
Defective immunoregulation in RSV vaccine-augmented viral lung disease restored by selective chemoattraction of regulatory T cells (2013) (64)
Role of CCL11 in Eosinophilic Lung Disease during Respiratory Syncytial Virus Infection (2005) (64)
Amplicon based MinION sequencing of SARS-CoV-2 and metagenomic characterisation of nasopharyngeal swabs from patients with COVID-19 (2020) (63)
Emerging drugs for respiratory syncytial virus infection (2009) (63)
Reduced Nasal Viral Load and IFN Responses in Infants with Respiratory Syncytial Virus Bronchiolitis and Respiratory Failure (2018) (62)
Current research on respiratory viral infections: Fourth International Symposium (2001) (61)
Detection of neutralising antibodies to SARS-CoV-2 to determine population exposure in Scottish blood donors between March and May 2020 (2020) (60)
Respiratory syncytial virus (RSV): a scourge from infancy to old age (2019) (60)
Flow cytometric analysis of pulmonary lymphocytes from mice infected with respiratory syncytial virus. (1989) (59)
Respiratory syncytial virus RNA in cells from the peripheral blood during acute infection. (1998) (59)
Abundant IFN-gamma production by local T cells in respiratory syncytial virus-induced eosinophilic lung disease. (1998) (57)
Nosocomial Pandemic (H1N1) 2009, United Kingdom, 2009–2010 (2011) (57)
Pre-Admission Statin Use and In-Hospital Severity of 2009 Pandemic Influenza A(H1N1) Disease (2011) (57)
Changes in in-hospital mortality in the first wave of COVID-19: a multicentre prospective observational cohort study using the WHO Clinical Characterisation Protocol UK (2021) (56)
Pulmonary Vγ4+ γδ T Cells Have Proinflammatory and Antiviral Effects in Viral Lung Disease1 (2009) (56)
Physical, cognitive and mental health impacts of COVID-19 following hospitalisation: a multi-centre prospective cohort study (2021) (56)
Interleukin 18 Coexpression during Respiratory Syncytial Virus Infection Results in Enhanced Disease Mediated by Natural Killer Cells (2010) (56)
COVID-19: Lessons from SARS and MERS. (2020) (54)
Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial (2019) (53)
Childhood infections, the developing immune system, and the origins of asthma. (2004) (53)
Respiratory Syncytial Virus: Targeting the G Protein Provides a New Approach for an Old Problem (2017) (53)
Antiviral and lung protective activity of a novel respiratory syncytial virus fusion inhibitor in a mouse model (2010) (52)
Helper T cell recognition of respiratory syncytial virus in mice. (1988) (51)
International Severe Acute Respiratory and emerging Infections Consortium Partners^ (2016) (51)
Respiratory syncytial virus infection provokes airway remodelling in allergen‐exposed mice in absence of prior allergen sensitization (2008) (50)
Antiviral immune responses and lung inflammation after respiratory syncytial virus infection. (2005) (50)
Hospital-acquired SARS-CoV-2 infection in the UK's first COVID-19 pandemic wave (2021) (49)
COVID-19 symptoms at hospital admission vary with age and sex: results from the ISARIC prospective multinational observational study (2021) (49)
The Chemokine MIP1α/CCL3 Determines Pathology in Primary RSV Infection by Regulating the Balance of T Cell Populations in the Murine Lung (2010) (49)
The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells with potent antiviral effects in vitro and in vivo (2005) (49)
Crossing barriers: infections of the lung and the gut (2008) (49)
Protective and disease-enhancing immune responses induced by recombinant modified vaccinia Ankara (MVA) expressing respiratory syncytial virus proteins. (2004) (48)
Current concepts and progress in RSV vaccine development (2014) (48)
A haemagglutination test for rapid detection of antibodies to SARS-CoV-2 (2020) (47)
Functional characterization of alloreactive T cells identifies CD25 and CD71 as optimal targets for a clinically applicable allodepletion strategy. (2010) (47)
Potential therapeutic implications of new insights into respiratory syncytial virus disease (2002) (46)
Global and Regional Burden of Hospital Admissions for Pneumonia in Older Adults: A Systematic Review and Meta-Analysis. (2019) (45)
Global and Regional Burden of Hospital Admissions for Pneumonia in Older Adults: A Systematic Review and Meta-Analysis. (2019) (45)
Natural killer cell NKG2D and granzyme B are critical for allergic pulmonary inflammation⋆ (2014) (44)
Accidental infection of laboratory worker with recombinant vaccinia virus (1991) (43)
IL-9 Regulates Pathology during Primary and Memory Responses to Respiratory Syncytial Virus Infection1 (2009) (43)
Clinical and laboratory features distinguishing pandemic H1N1 influenza-related pneumonia from interpandemic community-acquired pneumonia in adults (2011) (43)
Transcriptional profiling unveils type I and II interferon networks in blood and tissues across diseases (2019) (42)
Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study (2021) (42)
Non-steroidal anti-inflammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study (2021) (42)
Protective and harmful effects of viral infections in childhood on wheezing disorders and asthma. (2000) (42)
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge (2022) (40)
Neonatal antibody responses are attenuated by interferon-γ produced by NK and T cells during RSV infection (2013) (40)
Genetic Susceptibility to the Delayed Sequelae of Neonatal Respiratory Syncytial Virus Infection Is MHC Dependent (2010) (40)
Association Between Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection in Early Life and Recurrent Wheeze and Asthma in Later Childhood. (2019) (39)
Attenuated Bordetella pertussis vaccine protects against respiratory syncytial virus disease via an IL-17-dependent mechanism. (2013) (38)
Asthma and the common cold: can viruses imitate worms? (1994) (38)
Seasonal and pandemic influenza: 100 years of progress, still much to learn (2020) (38)
M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza (2017) (38)
Human microbial challenge: the ultimate animal model. (2012) (38)
Delayed Sequelae of Neonatal Respiratory Syncytial Virus Infection Are Dependent on Cells of the Innate Immune System (2013) (38)
Cost of Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infection Management in Young Children at the Regional and Global Level: A Systematic Review and Meta-Analysis. (2020) (37)
The protective effect of childhood infections (2001) (37)
Delivery of Cytokines by Recombinant Virus in Early Life Alters the Immune Response to Adult Lung Infection (2010) (36)
Predominance of heterosubtypic IFN‐γ‐only‐secreting effector memory T cells in pandemic H1N1 naive adults (2012) (36)
A Systematic Review of Clinical Practice Guidelines for the Diagnosis and Management of Bronchiolitis. (2020) (36)
Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses (2021) (35)
Recombinant respiratory syncytial virus lacking secreted glycoprotein G is attenuated, non-pathogenic but induces protective immunity. (2004) (34)
Epitope-specific airway-resident CD4+ T cell dynamics during experimental human RSV infection (2019) (33)
Amplicon-Based Detection and Sequencing of SARS-CoV-2 in Nasopharyngeal Swabs from Patients With COVID-19 and Identification of Deletions in the Viral Genome That Encode Proteins Involved in Interferon Antagonism (2020) (33)
Obesity, Ethnicity, and Risk of Critical Care, Mechanical Ventilation, and Mortality in Patients Admitted to Hospital with COVID‐19: Analysis of the ISARIC CCP‐UK Cohort (2021) (31)
Differences between asthmatics and nonasthmatics hospitalised with influenza A infection (2012) (30)
Contribution of cytokines to pathology and protection in virus infection. (2011) (30)
Absorption of Nasal and Bronchial Fluids: Precision Sampling of the Human Respiratory Mucosa and Laboratory Processing of Samples (2018) (30)
Virally Delivered Cytokines Alter the Immune Response to Future Lung Infections (2007) (30)
Preexposure to CpG Protects against the Delayed Effects of Neonatal Respiratory Syncytial Virus Infection (2012) (29)
Benefit and harm from immunity to respiratory syncytial virus: implications for treatment (2012) (29)
Prior Exposure to Live Mycobacterium bovis BCG Decreases Cryptococcus neoformans-Induced Lung Eosinophilia in a Gamma Interferon-Dependent Manner (2003) (29)
Global outbreak research: harmony not hegemony (2020) (28)
Preparing for a challenging winter 2020/21 (2020) (28)
Toward unified molecular surveillance of RSV: A proposal for genotype definition (2020) (27)
Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses (2021) (27)
Potential mechanisms causing delayed effects of respiratory syncytial virus infection. (2001) (26)
Respiratory syncytial virus and other pneumoviruses: a review of the international symposium--RSV 2003. (2004) (25)
Issues in vaccinology: Present challenges and future directions (2017) (25)
The mouse model of respiratory syncytial virus disease. (2013) (24)
What does the peripheral blood tell you in SARS? (2004) (24)
Respiratory syncytial virus and wheeze (1999) (23)
Acute kidney injury in patients hospitalized with COVID-19 from the ISARIC WHO CCP-UK Study: a prospective, multicentre cohort study (2021) (23)
Development of vaccines against common colds. (2002) (23)
Nasosorption as a Minimally Invasive Sampling Procedure: Mucosal Viral Load and Inflammation in Primary RSV Bronchiolitis (2017) (23)
Respiratory Syncytial Virus-Associated Hospital Admissions in Children Younger Than 5 Years in 7 European Countries Using Routinely Collected Datasets. (2020) (21)
Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza (2018) (21)
Increased aeroallergen‐specific interleukin‐4‐producing T cells in asthmatic adults (2002) (20)
Circulating histones play a central role in COVID-19-associated coagulopathy and mortality (2021) (20)
Impact of the 2009 influenza pandemic (2010) (20)
Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study (2020) (20)
Patterns of systemic and local inflammation in patients with asthma hospitalised with influenza (2019) (20)
Gene-gun DNA vaccination aggravates respiratory syncytial virus-induced pneumonitis. (2004) (19)
Obesity, chronic disease, age, and in-hospital mortality in patients with covid-19: analysis of ISARIC clinical characterisation protocol UK cohort (2021) (19)
Mouse gamma delta TCR+NK1.1+ thymocytes specifically produce interleukin-4, are major histocompatibility complex class I independent, and are developmentally related to alpha beta TCR+NK1.1+ thymocytes. (1996) (19)
Respiratory Syncytial Virus-Associated Acute Lower Respiratory Infections in Children With Bronchopulmonary Dysplasia: Systematic Review and Meta-Analysis. (2019) (19)
The Comparative Clinical Course of Pregnant and Non-Pregnant Women Hospitalised with Influenza A(H1N1)pdm09 Infection (2012) (19)
A high fat diet increases influenza A virus-associated cardiovascular damage. (2020) (18)
Using imaging to combat a pandemic: rationale for developing the UK National COVID-19 Chest Imaging Database (2020) (18)
Polylactide-co-glycolide (PLG) microparticles modify the immune response to DNA vaccination. (2008) (18)
The Helminth-Derived Immunomodulator AvCystatin Reduces Virus Enhanced Inflammation by Induction of Regulatory IL-10+ T Cells (2016) (18)
M1-like monocytes are a major immunological determinant of severity in previously healthy adults with life-threatening influenza. (2017) (18)
An improved protocol for measuring cytotoxic T cell activity in anatomic compartments with low cell numbers. (2001) (18)
Respiratory viruses and asthma: can the effects be prevented? (1998) (18)
Co-Infections, Secondary Infections, and Antimicrobial Usage in Hospitalised Patients with COVID-19 from the ISARIC WHO CCP-UK Study: A Prospective, Multicentre Cohort Study (2021) (17)
1670O Prospective data of first 1,797 hospitalised patients with cancer and COVID-19 derived from the COVID-19 Clinical Information Network and international Severe Acute Respiratory and emerging Infections Consortium, WHO Coronavirus Clinical Characterisation Consortium (2020) (17)
The effect of IL-12 treatment on vaccine-enhanced illness during infection with respiratory syncytial virus. (1998) (17)
Robust, reproducible clinical patterns in hospitalised patients with COVID-19 (2020) (17)
Infections prevent the development of asthma—true, false or both? (1999) (16)
Intracellular IFN-γ expression in natural killer cells precedes lung CD8MT cell recruitment during respiratory syncytial virus infection (1998) (16)
Nasal Lipopolysaccharide Challenge and Cytokine Measurement Reflects Innate Mucosal Immune Responsiveness (2015) (15)
OX40 Ligand and Programmed Cell Death 1 Ligand 2 Expression on Inflammatory Dendritic Cells Regulates CD4 T Cell Cytokine Production in the Lung during Viral Disease (2012) (15)
Author Correction: Progression of whole-blood transcriptional signatures from interferon-induced to neutrophil-associated patterns in severe influenza (2019) (15)
Acute Lower Respiratory Infections Associated With Respiratory Syncytial Virus in Children With Underlying Congenital Heart Disease: Systematic Review and Meta-analysis. (2019) (15)
Recent developments in the biology of respiratory syncytial virus: are vaccines and new treatments just round the corner? (1999) (15)
Local and Systemic Immunity Against RSV Induced by a Novel Intranasal Vaccine: A Randomised, Double- Blind, Placebo-Controlled Trial. (2019) (15)
COVID-19 pneumothorax in the UK: a prospective observational study using the ISARIC WHO clinical characterisation protocol (2021) (14)
Importance of patient bed pathways and length of stay differences in predicting COVID-19 hospital bed occupancy in England (2021) (14)
Single cell analysis of cytokine expression kinetics by human CD4+ T‐cell clones during activation or tolerance induction (2000) (14)
Prospective validation of the 4C prognostic models for adults hospitalised with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol (2021) (14)
Safety and efficacy of immune-stimulating complex-based antigen delivery systems for neonatal immunisation against respiratory syncytial virus infection. (2004) (13)
Offspring born to influenza A virus infected pregnant mice have increased susceptibility to viral and bacterial infections in early life (2021) (13)
Inhibition of T 1 / ST 2 during Respiratory Syncytial Virus Infection Prevents T Helper Cell Type 2 ( Th 2 )-but not Th 1-driven Immunopathology (2001) (13)
Comparison of CATs, CURB-65 and PMEWS as Triage Tools in Pandemic Influenza Admissions to UK Hospitals: Case Control Analysis Using Retrospective Data (2012) (13)
Third human challenge trial conference, Oxford, United Kingdom, February 6-7, 2020, a meeting report. (2020) (12)
Live Attenuated B. pertussis BPZE1 Rescues the Immune Functions of Respiratory Syncytial Virus Infected Human Dendritic Cells by Promoting Th1/Th17 Responses (2014) (12)
CD 25 + natural regulatory T cells are critical in limiting innate and adaptive immunity and resolving disease following respiratory syncytial virus infection (2010) (12)
Whole genome sequencing identifies multiple loci for critical illness caused by COVID-19 (2021) (11)
Partners in crime: co‐infections in the developing world (2000) (11)
Proposal for Human Respiratory Syncytial Virus Nomenclature below the Species Level (2021) (11)
Effect of ethnicity on care pathway and outcomes in patients hospitalized with influenza A(H1N1)pdm09 in the UK (2014) (11)
The burden of respiratory syncytial virus in healthy term-born infants in Europe: a prospective birth cohort study (2022) (11)
Endogenous IL-21 regulates pathogenic mucosal CD4 T-cell responses during enhanced RSV disease in mice (2012) (11)
Antivirals for influenza: where now for clinical practice and pandemic preparedness? (2014) (11)
Differential expression of CD40, OX40L & PDL2 on lung dendritic cells in polarised immune responses to Respiratory Syncytial Virus (RSV) (2007) (11)
Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study (2022) (10)
Implementation of corticosteroids in treatment of COVID-19 in the ISARIC WHO Clinical Characterisation Protocol UK: prospective, cohort study (2022) (10)
Increased nasal mucosal interferon and CCL13 response to a TLR7/8 agonist in asthma and allergic rhinitis. (2020) (10)
Estimating Transmission Parameters for Respiratory Syncytial Virus and Predicting the Impact of Maternal and Pediatric Vaccination. (2020) (10)
Changes in UK hospital mortality in the first wave of COVID-19: the ISARIC WHO Clinical Characterisation Protocol prospective multicentre observational cohort study (2020) (10)
Aetiology of acute respiratory infection in preschool children requiring hospitalisation in Europe—results from the PED-MERMAIDS multicentre case–control study (2021) (10)
Viva Europa, a Land of Excellence in Research and Innovation for Health and Wellbeing (2017) (10)
Outcome of hospitalisation for COVID-19 in patients with Interstitial Lung Disease: An international multicentre study. (2020) (10)
Development and validation of the 4C Deterioration model for adults hospitalised with COVID-19 (2020) (9)
Elevated antiviral, myeloid and endothelial inflammatory markers in severe COVID-19 (2020) (9)
Evaluation of the effectiveness of remdesivir in treating severe COVID-19 using data from the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, national cohort study. (2021) (9)
Induction of innate cytokine responses by respiratory mucosal challenge with R848 in zebrafish, mice, and humans (2019) (9)
Vaccines in the Prevention of Viral Pneumonia. (2017) (9)
Using correlates to accelerate vaccinology. (2022) (9)
Impact of cardiometabolic multimorbidity and ethnicity on cardiovascular/renal complications in patients with COVID-19 (2021) (8)
Procalcitonin Is Not a Reliable Biomarker of Bacterial Coinfection in People With Coronavirus Disease 2019 Undergoing Microbiological Investigation at the Time of Hospital Admission (2022) (8)
Simultaneous Viral Whole-Genome Sequencing and Differential Expression Profiling in Respiratory Syncytial Virus Infection of Infants. (2020) (8)
Simultaneous Viral Whole-Genome Sequencing and Differential Expression Profiling in Respiratory Syncytial Virus Infection of Infants. (2020) (8)
Enhance the Severity of Illness in CD8 T Respiratory Syncytial Virus But Do Not Eosinophilia to the Attachment Protein of IL-12-Activated NK Cells Reduce Lung (2000) (8)
Cancer datasets and the SARS-CoV-2 pandemic: establishing principles for collaboration (2020) (8)
Rapid selection of P323L in the SARS-CoV-2 polymerase (NSP12) in humans and non-human primate models and confers a large plaque phenotype (2021) (8)
Hospital Admission Trends for Bronchiolitis in Scotland, 2001-2016: A National Retrospective Observational Study. (2020) (8)
Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus (2021) (8)
Respiratory syncytial virus, airway inflammation and FEV1 decline in patients with COPD: Am J Respir Crit Care Med 2006; published online ahead of print on 2 February 2006 as doi:10.1164/rccm.200509-1489OC (2006) (7)
Hot topics in the prevention of respiratory syncytial virus disease (2011) (7)
Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study (2022) (7)
Influenza vaccination: lessons learned from the pandemic (H1N1) 2009 influenza outbreak (2010) (7)
RSV 2005: Global impact, changing concepts, and new challenges. (2005) (7)
Comparison of children and young people admitted with SARS-CoV-2 across the UK in the first and second pandemic waves: prospective multicentre observational cohort study (2021) (7)
RSV bronchiolitis, γδ T cells and asthma: are they linked? (2003) (7)
ISARIC COVID-19 Clinical Data Report: 8 June 2020 (2020) (7)
Innate-like Gene Expression of Lung-resident Memory CD8+ T-cells During Experimental Human Influenza: A Clinical Study. (2021) (7)
Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses (2021) (7)
Comparison of UK paediatric SARS-CoV-2 admissions across the first and second pandemic waves (2022) (7)
Regulatory T Cells Prevent Th 2 Immune Responses and Pulmonary Eosinophilia during Respiratory Syncytial Virus Infection in Mice (2013) (7)
OMIP‐062: A 14‐Color, 16‐Antibody Panel for Immunophenotyping Human Innate Lymphoid, Myeloid and T Cells in Small Volumes of Whole Blood and Pediatric Airway Samples (2019) (7)
MHC and antigen presentation. (1989) (6)
Current research on respiratory viral infections: Fifth International Symposium☆ (2004) (6)
Clinical characteristics of children and young people hospitalised with covid-19 in the United Kingdom: prospective multicentre observational cohort study (2020) (6)
Detection and quantification of antibody to SARS CoV 2 receptor binding domain provides enhanced sensitivity, specificity and utility (2022) (6)
Corticosteroid Use in Otolaryngology: Current Considerations During the COVID-19 Era (2021) (6)
Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses (2022) (6)
Mapping of SARS-CoV-2 IgM and IgG in gingival crevicular fluid: Antibody dynamics and linkage to severity of COVID-19 in hospital inpatients (2022) (6)
RSV Takes Control of Neonatal Breg Cells: Two Hands on the Wheel. (2017) (5)
Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU). (2020) (5)
An Evaluation of Community Assessment Tools (CATs) in Predicting Use of Clinical Interventions and Severe Outcomes during the A(H1N1)pdm09 Pandemic (2013) (5)
Vitamin D insufficiency in COVID-19 and influenza A, and critical illness survivors: a cross-sectional study (2021) (5)
Presumed Risk Factors and Biomarkers for Severe Respiratory Syncytial Virus Disease and Related Sequelae: Protocol for an Observational Multicenter, Case-Control Study From the Respiratory Syncytial Virus Consortium in Europe (RESCEU). (2020) (5)
A Gene Expression Signature for RSV: Clinical Implications and Limitations (2013) (5)
RSV bronchiolitis, gammadelta T cells and asthma: are they linked? (2003) (5)
Immunological and Inflammatory Biomarkers of Susceptibility and Severity in Adult Respiratory Syncytial Virus Infections. (2020) (5)
Vaccination policies in Europe: Common goals, diverse approaches and public doubts (2018) (5)
Therapeutic blockade of granulocyte macrophage colony-stimulating factor (GM-CSF) in COVID-19-associated hyperinflammation: opportunities and challenges (2020) (4)
Inhaled corticosteroids: not just for asthma, but for COVID-19? (2022) (4)
Towards nationally curated data archives for clinical radiology image analysis at scale: Learnings from national data collection in response to a pandemic (2021) (4)
Analysis of SARS-CoV-2 known and novel subgenomic mRNAs in cell culture, animal model, and clinical samples using LeTRS, a bioinformatic tool to identify unique sequence identifiers (2022) (4)
Unveiling the Risk Period for Death After Respiratory Syncytial Virus Illness in Young Children Using a Self-Controlled Case Series Design. (2020) (4)
Clonal hematopoiesis is not significantly associated with COVID-19 disease severity (2022) (4)
Chapter 32 – Beneficial and Harmful Immune Responses in the Respiratory Tract (1996) (4)
Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages (2022) (4)
COVID-19 and beyond: a call for action and audacious solidarity to all the citizens and nations, it is humanity’s fight (2020) (4)
Mucosal Immune Responses to Respiratory Syncytial Virus (2022) (4)
Sequence analysis of SARS-CoV-2 in nasopharyngeal samples from patients with COVID-19 illustrates population variation and diverse phenotypes, placing the in vitro growth properties of B.1.1.7 and B.1.351 lineage viruses in context (2021) (4)
Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol (2020) (3)
A Systematic Review and Meta-analysis of Animal Studies Investigating the Relationship Between Serum Antibody, T Lymphocytes, and Respiratory Syncytial Virus Disease. (2021) (3)
Erratum: RSV-specific airway resident memory CD8+ T cells and differential disease severity after experimental human infection (2016) (3)
Immune tolerance to hepatitis C virus acquired during engraftment of bone marrow transplant (2005) (3)
Outcome of COVID-19 in hospitalised immunocompromised patients: An analysis of the WHO ISARIC CCP-UK prospective cohort study (2022) (3)
Genetic influences on the induction of eosinophilic pathology during lung viral infection (1997) (3)
Role of CCL 11 in Eosinophilic Lung Disease during Respiratory Syncytial Virus Infection (2005) (3)
Alternative pathway dysregulation in tissues drives sustained complement activation and predicts outcome across the disease course in COVID‐19 (2022) (3)
Vaccines for the prevention of respiratory viral infections: problems and current status (2004) (3)
T-cells in respiratory syncytial virus (RSV) infection. (1989) (3)
FIXED-BED TECHNOLOGY PURIFIES RICH GAS WITH H2S, HG (1999) (3)
Biphasic activation of complement and fibrinolysis during the human nasal allergic response (2018) (3)
Admission Blood Glucose Level and Its Association With Cardiovascular and Renal Complications in Patients Hospitalized With COVID-19. (2022) (3)
Men and Women in Immunology: Closing the gap on gender parity? (2018) (2)
Resilience of the respiratory microbiome in controlled adult RSV challenge study (2021) (2)
Detection and Quantification of Antibody to SARS-CoV-2 Receptor Binding Domain Provides Enhanced Sensitivity, Specificity and Utility (2021) (2)
The Respiratory Mucosa: Front and Center in Respiratory Syncytial Virus Disease (2019) (2)
Immunological determinants of disease caused by respiratory syncytial virus. (1996) (2)
Faculty Opinions recommendation of Respiratory syncytial virus and recurrent wheeze in healthy preterm infants. (2013) (2)
Functional Characterisation of Alloreactive T-Cells Identifies CD25 and CD71 as the Optimal Targets for Allodepletion Strategies. (2007) (2)
CD4+ Tcells clear virus butaugmentdisease inmiceinfected withrespiratory syncytial virus. Comparison withtheeffects ofCD8+ T cells (1992) (2)
Comparative evaluation of ten lateral flow immunoassays to detect SARS-CoV-2 antibodies (2021) (2)
Impact of Dexamethasone and Remdesivir on Neurological Complications during COVID-19 (2022) (2)
LSC Abstract – The AsthmaMap: Towards a community-driven reconstruction of asthma-relevant pathways and networks (2016) (2)
Clinical and Viral Factors Associated With Disease Severity and Subsequent Wheezing in Infants With Respiratory Syncytial Virus Infection. (2022) (2)
Asthma patients hospitalized with influenza lack mucosal and systemic type 2 inflammation (2016) (1)
Natural killer cell NKG 2 D and granzyme B are critical for allergic pulmonary inflammation q (2014) (1)
The Effect of Vitamin D Supplementation on Mucosal IL-5, MMP9 and Cathelicidin after Nasal Allergen Challenge with Grass Pollen (2016) (1)
Symptom‐based case definitions for COVID‐19: Time and geographical variations for detection at hospital admission among 260,000 patients (2022) (1)
T cells take the inside track (2006) (1)
Identification of HLA-DR11-restricted CD4+T cell epitopes derived from hepatitis C virus (2000) (1)
Late-breaking abstract: Relationship of asthma to outcome in influenza A/H1N1 2009 infection: FLU-CIN cohort study (2011) (1)
Fewer COVID‐19 Neurological Complications with Dexamethasone and Remdesivir (2022) (1)
of Birmingham Features of 20133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol (2020) (1)
Enhanced in vivo mucosal interferon and chemokine responses to a single stranded RNA analogue (R848) in participants with asthma (2019) (1)
Divergent age-related humoral correlates of protection against respiratory syncytial virus infection in older and young adults: a pilot, controlled, human infection challenge model. (2022) (1)
Where is SARS now? (2003) (1)
Faculty Opinions recommendation of A very rapid and simple assay based on trogocytosis to detect and measure specific T and B cell reactivity by flow cytometry. (2006) (1)
Barcelona's asthma epidemics. (1992) (1)
Pandemic, Epidemic, Endemic: B Cell Repertoire Analysis Reveals Unique Anti-Viral Responses to SARS-CoV-2, Ebola and Respiratory Syncytial Virus (2021) (1)
How should influenza be treated? Focus on antivirals. (2015) (1)
Neuraminidase inhibitors for influenza complications–Authors' reply (2014) (1)
Identification of novel mechanistically distinct endotypes of pandemic influenza-associated acute respiratory failure (2020) (1)
Cost-effectiveness of respiratory syncytial virus preventive interventions in children: a model comparison study. (2022) (1)
Controlled Human Infection Challenge Studies with RSV. (2022) (1)
Maternal immunisation 1 Maternal immunisation: a worldwide landscape analysis [A: title edited to be more descriptive and explanatory] (2017) (1)
The role of public involvement in the design of the first SARS-CoV-2 human challenge study during an evolving pandemic (2022) (1)
Respiratory support in patients with severe COVID-19 in the International Severe Acute Respiratory and Emerging Infection (ISARIC) COVID-19 study: a prospective, multinational, observational study (2022) (1)
A New Role for CXCL4 in Respiratory Syncytial Virus Disease (2020) (1)
Identification and quantification of SARS-CoV-2 leader subgenomic mRNA gene junctions in nasopharyngeal samples shows phasic transcription in animal models of COVID-19 and dysregulation at later time points that can also be identified in humans (2021) (1)
CYTOTOXIC T CELLS CLEAR VIRUS BUT AUGMENT LUNG PATHOLOGY IN MICE INFECTED WITH RESPIRATORY SYNCYTIAL VIRUS Brief Definitive Report (2003) (0)
Doctors accepting flu vaccination is the sensible and responsible choice (2011) (0)
The Effect of RSV Infection on the Respiratory Microbiome of Adults (2020) (0)
Common, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity (2021) (0)
COVID-19: Lessons from SARS and MERS. (2020) (0)
Lung NKT cells modulate NK and T cell activity to drive Th2 responses during respiratory viral infection (2011) (0)
Non-steroidal anti-inﬂammatory drug use and outcomes of COVID-19 in the ISARIC Clinical Characterisation Protocol UK cohort: a matched, prospective cohort study (2021) (0)
Kinetics of intracellular cytokine expression by monoclonal and polyclonal human T cells (1997) (0)
Severe Respiratory Failure in Adult Influenza Infection Is Characterised by Mechanisms Relating to Pulmonary Endothelial Leak and Interferon Gamma Induced Translational Silencing (2020) (0)
Virus Infection Is MHC Dependent Sequelae of Neonatal Respiratory Syncytial Genetic Susceptibility to the Delayed (2010) (0)
Vector control to eliminate artemisinin resistant malaria in the Greater Mekong subregion (2014) (0)
G37(P) Laboratory correlates of severity in acute bronchiolitis of infancy (2018) (0)
5. Respiratory Syncytial Virus (2018) (0)
Immunological and Inflammatory Biomarkers of Susceptibility and Severity in Adult Respiratory Syncytial Virus (RSV) Infections (2020) (0)
SARS-CoV-2 infection is associated with anti-desmoglein 2 autoantibody detection. (2022) (0)
The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection (2023) (0)
Transcriptional profiling unveils type I and II interferon networks in blood and tissues across diseases (2019) (0)
COVID-19 and beyond: a call for action and audacious solidarity to all the citizens and nations, it is humanity’s fight [version 1; peer review: 3 approved with reservations] (2021) (0)
Local and Systemic Immunity against Respiratory Syncytial Virus Induced by a Novel Intranasal Vaccine A Randomized, Double-Blind, Placebo-controlled Clinical Trial Induces Durable (2019) (0)
Edinburgh Research Explorer Characterization of the domestic goat T cell receptor gene loci and gene usage (2021) (0)
Susan Elizabeth Openshaw (née Scott Stokes) (2008) (0)
SARS-CoV-2 antibody responses associate with sex, age and disease severity in previously uninfected people admitted to hospital with COVID-19: An ISARIC4C prospective study (2023) (0)
260. Corticosteroid treatment in influenza virus and SARS-CoV-2 co-infected patients (2022) (0)
OX40L and PD-L2 expression on inflammatory dendritic cells regulates CD4 T cell cytokine production in the lung during viral disease (2012) (0)
Authors' response (2011) (0)
COVID-19 and Beyond: A Call for Action and Audacious Solidarity to All the Citizens and Nations, It Is Humanity’s Fight (2020) (0)
THE CAUSE OF VENOUS ULCERATION (1982) (0)
Faculty Opinions recommendation of Severe human lower respiratory tract illness caused by respiratory syncytial virus and influenza virus is characterized by the absence of pulmonary cytotoxic lymphocyte responses. (2007) (0)
Channel Tunnel Rail Link – Contract 220 Graham Road Deep Vent Shaft (2004) (0)
Animal Models of Viral Respiratory Infections (2003) (0)
Viral Disease Cytokine Production in the Lung during Dendritic Cells Regulates CD 4 T Cell Ligand 2 Expression on Inflammatory OX 40 Ligand and Programmed Cell Death 1 (2012) (0)
COVID-19 and beyond: a call for action and audacious solidarity to all the citizens and nations, it is humanity’s fight [version 1; peer review: awaiting peer review] (2020) (0)
Faculty Opinions recommendation of Neutrophil extracellular traps kill bacteria. (2004) (0)
Viral Coinfections in Hospitalized Coronavirus Disease 2019 Patients Recruited to the International Severe Acute Respiratory and Emerging Infections Consortium WHO Clinical Characterisation Protocol UK Study (2022) (0)
Human infection challenge vaccine (HIC-vac) network (2019) (0)
Virus Infection Enhancement during Respiratory Syncytial Immune Responses and Disease (2005) (0)
Respiratory syncytial virus infection provokes airway remodelling in allergen‐exposed mice in absence of prior allergen sensitization (2008) (0)
T Cells After Clearance of Hepatitis C Virus + Evolution of Epitope-Specific Memory CD 4 Openshaw (2002) (0)
Flowcytometric analysis ofpulmonarylymphocytes frommiceinfected withrespiratory syncytial virus (1989) (0)
Lymphocytosis in Cells Recovered by Bronchoalveolar Lavage from Mice Infected with Human Respiratory Syncytial Virus (1987) (0)
Characterisation of epitope-specific functionally distinct CD4+memory cell populations after clearance of hepatitis C virus (HCV) (2002) (0)
COVID-19: Lessons from SARS and MERS. (2020) (0)
Faculty Opinions recommendation of Mature CD8(+) T lymphocyte response to viral infection during fetal life. (2003) (0)
The Respiratory Mucosa: Front and Center in RSV Disease. (2019) (0)
Faculty Opinions recommendation of The role of endosymbiotic Wolbachia bacteria in the pathogenesis of river blindness. (2002) (0)
Faculty Opinions recommendation of Enhanced survival of lung tissue-resident memory CD8⁺ T cells during infection with influenza virus due to selective expression of IFITM3. (2013) (0)
50: Enhanced depletion of alloreactive T cells using combined CD25/71 immunomagnetic selection (2007) (0)
Natural Regulatory T Cells Are Critical in Limiting Innate and Adaptive Immunity and Resolving Disease following Respiratory Syncytial Virus Infection (cid:1) † (2010) (0)
Publisher Correction: Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus (2021) (0)
Multimedia: Nature Medicine (1999) (0)
Plasma steroid profiles in patients hospitalised with COVID-19 - an ISARIC/WHO CCP-UK cohort study (2021) (0)
Rational and practical hurdles in vaccine development for respiratory disease (2014) (0)
Faculty Opinions recommendation of Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. (2005) (0)
1H NMR Signals from Urine Excreted Protein Are a Source of Bias in Probabilistic Quotient Normalization (2022) (0)
A New Role for CXCL4 in RSV Disease. (2020) (0)
Faculty Opinions recommendation of Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigms. (2013) (0)
Respiratory syncytial virus vaccine development (2015) (0)
IL-12 abbrogates Th2 and B cell responses but has no effect on viral vaccine enhanced illness (1997) (0)
Contribution of Individual Proteins of Respiratory Syncytial Virus (RSV) to Immunopathology in the Lung (1989) (0)
Activation of the Complement, Coagulation and Fibrinolysis Pathways after Nasal Allergen Challenge (2017) (0)
Cover (2020) (0)
Regulation of immunity during viral lung infection (2011) (0)
Viral co-infections in hospitalised COVID-19 patients recruited to the ISARIC WHO CCP-UK study (2022) (0)
Gas purification in the dense phase at the CATS terminal (1999) (0)
COVID-19: Challenges and solutions: Updates on treatment, vaccines and prophylaxis (2020) (0)
Syncytial Virus Infection and Memory Responses to Respiratory IL-9 Regulates Pathology during Primary (2009) (0)
Plasma steroid concentrations reflect disease severity during acute illness but not recovery after hospitalisation with COVID-19 (2022) (0)
Response from Openshaw (1994) (0)
Current concepts and progress in RSV vaccine (2014) (0)
A41 Deep sequencing of respiratory syncytial virus links viral diversity to disease severity (2019) (0)
The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection (2023) (0)
Abstracts of the British Society for Immunology Annual Congress, 1-4 December 2014, Brighton, UK. (2014) (0)
Maternal immunisation 1 Maternal immunisation : collaborating with mother nature (2017) (0)
Respiratory Syncytial Virus Infection Vaccine-Induced Eosinophilia During Host Genetic Determinants of Matthews (1998) (0)
Respiratory Syncytial Virus (RSV) Detection Is Associated with an Increased Inflammatory Response in Stable (non-Exacerbating) Chronic Obstructive Pulmonary Disease (COPD) Patients (2019) (0)
Respiratory viruses: New frontiers—a Keystone Symposia report (2023) (0)
VACCINATIONS | Viral (2006) (0)
Regulation of immunity during viral lung infection (168.1) (2011) (0)
Faculty Opinions recommendation of Increased replication of respiratory syncytial virus (RSV) in pulmonary infiltrates is associated with enhanced histopathological disease in bonnet monkeys (Macaca radiata) pre-immunized with a formalin-inactivated RSV vaccine. (2002) (0)
Long Covid: clues about causes (2023) (0)
Whole genome sequencing reveals host factors underlying critical Covid-19 Accelerated Article Preview (2022) (0)
Defense Against Viruses at the Respiratory Mucosa: Right Place, Right Time, Right Response (2015) (0)
The role of innate lymphoid cells in early life lung infection (2018) (0)
Faculty Opinions recommendation of Identification of a dendritic cell receptor that couples sensing of necrosis to immunity. (2009) (0)

This paper list is powered by the following services:

Other Resources About Peter Openshaw

en.wikipedia.org

What Schools Are Affiliated With Peter Openshaw ?

Peter Openshaw is affiliated with the following schools:

Peter Openshaw 's Academic­Influence.com Rankings